AASLD Voice of China | Dr. Hong Tang’s Team: Multiple Research Achievements in the Fields of Hepatitis B, Hepatitis C, and Non-Alcoholic Fatty Liver D

AASLD Voice of China | Dr. Hong Tang’s Team: Multiple Research Achievements in the Fields of Hepatitis B, Hepatitis C, and Non-Alcoholic Fatty Liver D

2023.12.22
From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases Annual Meeting (AASLD2023) was held in Boston, USA. Professor Hong Tang's team from West China Hospital of Sichuan University presented multiple research studies in the fields of hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD) at the conference. The research was included in the conference proceedings and presented in the form of posters. Congratulations to the team! Hepatology Digest reports on these research findings, and the relevant content is summarized below.
Focusing on Hepatitis B, New Developments in the “Oasis” Project and Exploration of TAF’s Immune Modulation Effects

Focusing on Hepatitis B, New Developments in the “Oasis” Project and Exploration of TAF’s Immune Modulation Effects

2023.12.22
The annual highlight in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, is currently taking place in Boston, USA. Two research achievements related to the treatment and management of hepatitis B by Dr. Wenhong Zhang and Dr. Jiming Zhang 's team from Huashan Hospital, affiliated with Fudan University, have been included in the conference. One is a phase analysis of the Oasis Project, a study aimed at reducing the occurrence of liver cancer in Chinese hepatitis B patients, revealing the safety and benefits of interferon application in specific populations. The other explores the immune modulation effects of tenofovir alafenamide (TAF) treatment and predictive indicators of efficacy. "Hepatology Digest" hereby reports on these findings.
Dr. Qin Ning’s Team: Focus on Hepatitis B, Fatty Liver, Liver Injury, and End-Stage Liver Disease, Unveiling 8 Achievements at the AASLD Meeting

Dr. Qin Ning’s Team: Focus on Hepatitis B, Fatty Liver, Liver Injury, and End-Stage Liver Disease, Unveiling 8 Achievements at the AASLD Meeting

2023.12.21
From November 10th to 14th, 2023, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2023) was grandly held in Boston, USA. Dr. Qin Ning's team from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, presented 2 posters of distinction and 6 posters on scientific research in the fields of liver injury, fatty liver, hepatitis B, end-stage liver disease, and complications. "Hepatology Digest" hereby reports on some of the research abstracts, providing you with a glimpse of the team's achievements.